Company Overview
About Beta Bionics
Beta Bionics is a commercial-stage medical device company focused on transforming the management of insulin-requiring diabetes. Its flagship product is the iLet Bionic Pancreas, a device that automates insulin delivery using a proprietary adaptive algorithm that requires no carbohydrate counting, correction boluses, or manual basal rate programming from the user — the system learns from glucose readings and autonomously adjusts insulin delivery to maintain target glucose levels. The iLet is compatible with continuous glucose monitors including Dexcom G6, Dexcom G7, and FreeStyle Libre 3 Plus.
Business Model & Competitive Advantage
Beta Bionics completed its IPO on Nasdaq (ticker: BBNX) in January 2025, raising $234.6M including the full exercise of the underwriters'' overallotment option. The company reported Q1 2026 net sales of $27.6M, up 57% year-over-year, following full-year 2025 revenue growth that saw the iLet reach approximately 24,000 active users. In June 2025, Beta Bionics announced an integration agreement with Abbott to support Abbott''s future dual glucose-ketone sensor, expanding the iLet''s sensor compatibility pipeline. The company also released the Color iLet, an updated device with a full-color display for new patients.
Competitive Landscape 2025–2026
Beta Bionics'' differentiation lies in the iLet''s bionic pancreas algorithm, which is designed to be the most autonomous closed-loop system available — removing the cognitive burden of diabetes management that competing hybrid closed-loop systems still place on users. The company competes with Insulet''s Omnipod 5 and Medtronic''s MiniMed systems in the automated insulin delivery (AID) market, which is expanding as broader populations with type 1 and type 2 diabetes seek technology-assisted glucose management.
Key Differentiators
Strong Challenger
Beta Bionics is an established challenger with significant market presence and competitive offerings in Healthcare.
Frequently Asked Questions
Similar Brands
Abridge
Abridge is a Pittsburgh, Pennsylvania-based healthcare AI clinical documentation platform — backed with approximately $800 million in total funding including a $300 million Series E in June 2025 led b
Veeva Systems
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executiv
Oracle Health
Oracle Health is the healthcare technology business unit of Oracle Corporation (NYSE: ORCL) — providing electronic health records (EHR), clinical workflow management, health information exchange, reve
athenahealth
athenahealth is a cloud-based electronic health records (EHR), medical billing, and practice management company founded in 1997 and headquartered in Watertown, Massachusetts. The company was built on
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
Compare Beta Bionics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Beta Bionics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Beta Bionics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Beta Bionics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →